Arrowhead Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2836 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials - Aug 31st, 2026 9:02 am
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Aug 30th, 2026 9:30 am
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - Aug 28th, 2026 4:26 pm
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress - Aug 24th, 2026 5:30 am
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides - Aug 17th, 2026 7:33 am
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit - Aug 7th, 2026 4:02 am
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - Aug 6th, 2026 12:05 pm
ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG - Aug 5th, 2026 7:38 am
Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... - Aug 4th, 2026 11:05 pm
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights - Aug 4th, 2026 4:03 pm
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Aug 4th, 2026 2:01 pm
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher - Aug 4th, 2026 2:00 pm
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Aug 3rd, 2026 2:30 pm
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones - Jul 30th, 2026 3:09 am
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Jul 27th, 2026 5:30 am
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Jul 23rd, 2026 12:11 pm
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? - Jul 23rd, 2026 9:00 am
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Jul 22nd, 2026 4:44 pm